PGHL P & G Health Q4 FY25 results (Jan–Mar 2025) and concall
P&G Health Ltd. reported strong financial performance for the 9-month fiscal year ending March 31, 2025, with sales growing 8% to ₹918 crores and PAT increasing 27% to ₹234 crores. This growth was driven by the successful execution of its Integrated Growth Strategy, focusing on product superiority, retail expansion, and productivity, which yielded over ₹40 crores in savings. The company also saw strong traction in new product launches and gained market share in key categories like Nerve Care and Vitamin E, despite a challenging macroeconomic environment.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 313 | 310 | 311 |
| EBITDA | 114 | 123 | 81 |
| Net profit | 82 | 91 | 61 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
